PLB1004
Sponsors
Avistone Biotechnology Co., Ltd.
Conditions
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNon-Small-Cell Lung Cancer
Phase 1
Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT05347628
Start: 2020-08-25End: 2024-11-30Target: 91Updated: 2023-08-21
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
RecruitingNCT06046495
Start: 2024-07-08End: 2028-02-09Target: 81Updated: 2025-04-23
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
RecruitingNCT06343064
Start: 2023-06-13End: 2026-12-31Target: 156Updated: 2025-05-21
Phase 2
A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)
Active, not recruitingNCT06015503
Start: 2023-07-21End: 2026-12-30Target: 139Updated: 2026-05-22
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
RecruitingNCT06574347
Start: 2024-08-07End: 2027-07-31Target: 120Updated: 2025-05-21
Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations
RecruitingNCT07336732
Start: 2026-03-11End: 2029-01-01Target: 40Updated: 2026-03-20
Phase 3
Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.
Enrolling by invitationNCT06281964
Start: 2023-12-01End: 2030-06-30Target: 327Updated: 2026-04-23
Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure
Not yet recruitingNCT06970782
Start: 2025-05-15End: 2028-12-31Target: 278Updated: 2025-05-21